Ascendis Pharma ( (ASND) ) has issued an announcement.
On March 31, 2025, Ascendis Pharma announced the submission of a New Drug Application to the U.S. FDA for TransCon CNP (navepegritide), aimed at treating children with achondroplasia. This investigational prodrug is designed to offer continuous exposure of CNP to body tissues, including growth plates and skeletal muscle, based on extensive clinical trial data. The submission marks a significant step in addressing the needs of children with achondroplasia, potentially enhancing Ascendis Pharma’s position in the rare disease treatment market.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies for unmet medical needs. The company specializes in creating prodrugs that provide sustained release of active molecules, with a particular emphasis on endocrinology and rare diseases.
YTD Price Performance: 12.09%
Average Trading Volume: 476,500
Technical Sentiment Signal: Sell
Current Market Cap: $9.26B
See more insights into ASND stock on TipRanks’ Stock Analysis page.